Cargando…
Denosumab: A comprehensive review
The clinical sequelae from bone metastases, termed skeletal-related events (SREs), are among the most frequent and debilitating complications in patients with advanced cancer. Bone metastases are characterized by pathologically increased osteoclast activity, and accumulating evidence indicates that...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889059/ https://www.ncbi.nlm.nih.gov/pubmed/24455656 http://dx.doi.org/10.4103/2278-330X.119895 |
_version_ | 1782299152829382656 |
---|---|
author | Narayanan, Prasad |
author_facet | Narayanan, Prasad |
author_sort | Narayanan, Prasad |
collection | PubMed |
description | The clinical sequelae from bone metastases, termed skeletal-related events (SREs), are among the most frequent and debilitating complications in patients with advanced cancer. Bone metastases are characterized by pathologically increased osteoclast activity, and accumulating evidence indicates that tumor cells interact within the bone to stimulate the receptor activator of nuclear factor kB (RANK)-RANK ligand (RANKL) pathway. RANKL is an essential mediator of osteoclast formation, function, and survival. Because of the central role of RANKL in cancer-induced bone destruction, the inhibition of RANKL has the potential to result in the reduction of pathologic bone resorption. Denosumab is a fully human monoclonal antibody specific for RANKL that inhibits the formation, activation, and survival of osteoclasts. This in turn decreases bone resorption and reduces cancer-induced bone destruction. In this review, we give an overview of the drug Denosumab with its history, mechanism of action, clinical trial data, adverse effects, and future challenges. |
format | Online Article Text |
id | pubmed-3889059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-38890592014-01-16 Denosumab: A comprehensive review Narayanan, Prasad South Asian J Cancer Drug Review The clinical sequelae from bone metastases, termed skeletal-related events (SREs), are among the most frequent and debilitating complications in patients with advanced cancer. Bone metastases are characterized by pathologically increased osteoclast activity, and accumulating evidence indicates that tumor cells interact within the bone to stimulate the receptor activator of nuclear factor kB (RANK)-RANK ligand (RANKL) pathway. RANKL is an essential mediator of osteoclast formation, function, and survival. Because of the central role of RANKL in cancer-induced bone destruction, the inhibition of RANKL has the potential to result in the reduction of pathologic bone resorption. Denosumab is a fully human monoclonal antibody specific for RANKL that inhibits the formation, activation, and survival of osteoclasts. This in turn decreases bone resorption and reduces cancer-induced bone destruction. In this review, we give an overview of the drug Denosumab with its history, mechanism of action, clinical trial data, adverse effects, and future challenges. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3889059/ /pubmed/24455656 http://dx.doi.org/10.4103/2278-330X.119895 Text en Copyright: © South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Drug Review Narayanan, Prasad Denosumab: A comprehensive review |
title | Denosumab: A comprehensive review |
title_full | Denosumab: A comprehensive review |
title_fullStr | Denosumab: A comprehensive review |
title_full_unstemmed | Denosumab: A comprehensive review |
title_short | Denosumab: A comprehensive review |
title_sort | denosumab: a comprehensive review |
topic | Drug Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889059/ https://www.ncbi.nlm.nih.gov/pubmed/24455656 http://dx.doi.org/10.4103/2278-330X.119895 |
work_keys_str_mv | AT narayananprasad denosumabacomprehensivereview |